Work

Toxicities Associated With PD-1/PD-L1 Blockade

Year: 2018

Type: review

Abstract: Immune checkpoint inhibitors, particularly those targeting PD-1/PD-L1, produce durable responses in a subset of patients across cancer types. Although often well tolerated, these agents can induce a broad spectrum of autoimmune-like complications that may affect any organ system. Treatment of these toxicities primarily consists of immune suppression with corticosteroids and other agents. This review briefly discusses the mechanisms of immune-related adverse events, overviews the clinical and pathologic features of major toxicities caused by PD-1/PD-L1 blockade, and reviews their management.

Source: The Cancer Journal

DOI: 10.1097/ppo.0000000000000296

Authors: Daniel Y. Wang, Douglas B. Johnson, Elizabeth J. Davis

Institutions: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute